论文部分内容阅读
Currently there is no effective antiviral therapy for SARS-CoV-2 infection,which frequently leads to fatal inflammatory responses and acute lung injury.Here,we discuss the various mechanisms of SARS-CoV-mediated inflammation.We also assume that SARS-CoV-2 likely shares similar inflammatory responses.Potential therapeutic tools to reduce SARS-CoV-2 -induced inflammatory responses include various methods to block FcR activation.In the absence of a proven clinical FcR blocker,the use of intravenous immunoglobulin to block FcR activation may be a viable option for the urgent treatment of pulmonary inflammation to prevent severe lung injury.Such treatment may also be combined with systemic anti-inflammatory drugs or corticosteroids.However,these strategies,as proposed here,remain to be clinically tested for effectiveness.